Fundamental Data for GTXI

GTX INC(NSDQ:GTXI)

GTX Inc is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men''s health conditions. GTx''s drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens.

# Employees: 147

Address: 3 Ndunlap Street 3rd Floor Van Vleet Building,Memphis,TN,USA

Phone: 901-523-9700

Fax: 901-5239772

Website: www.gtxinc.com

Email: investor.relations@gtxinc.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Mitchell S. Steiner M.D. (Chmn.; C.E.O.)

Marc S. Hanover (Presi.; C.O.O.; Dir.)

Mark E. Mosteller (V.P.; C.F.O.; Treas.)

Henry P. Doggrell (V.P.; Gen. Consl.; Sec.)

Christopher K. West (V.P. Sales,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/16/2010

Mean EPS (Next Qtr): ($0.35)

Mean EPS (Year): ($1.32)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 6

Shares Performance

Period	GTXI	Compare to S&P
YTD	-77.55 %	-81.43 %
4 Weeks	-57.91 %	-60.04 %
12 Weeks	-61.43 %	-64.08 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1274848

Shares Outstanding: 36M

Market Cap: $0.14B

52 Week High: $18.28

52 Week Low: $3.27

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 GTXI split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -12.90 %

EPS Growth in Last Year: -6.06 %

Sales Growth in Last Quarter: -5.81 %

Sales Growth in Last Quarter: 18.07 %

Financials

Qtr Book Value: $6.30

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 9.800